ReviewCell communication and signaling : CCS2026
Large extracellular vesicles and blebbisomes in cancer: emerging and translational opportunities highlights.
Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Condensates on the Move: Midbody Remnants as Large, Translation-Competent Extracellular Vesicles.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026Review
- Extracellular vesicle-mediated immunomodulation and targeted delivery: breakthroughs and challenges in rheumatoid arthritis therapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Large extracellular vesicles (lEVs), particularly the recently identified blebbisomes, are emerging as critical mediators of tumor progression and intercellular communication. Compared with small vesicles, lEVs exhibit pronounced heterogeneity in size, cargo composition, and mechanisms of biogenesis. While EVs of all sizes can carry proteins, nucleic acids, lipids, and metabolites, lEVs more frequently encapsulate bulky cargos-including intact organelles such as mitochondria-reflecting their size-enabled loading capacity rather than a feature unique to lEVs. These characteristics position lEVs as key regulators of immune responses, metabolic reprogramming, and the establishment of pre-metastatic niches within the tumor microenvironment. Blebbisomes, distinguished by their dynamic membrane behavior, bidirectional cargo transfer, and high expression of immunosuppressive molecules, represent a novel paradigm in extracellular communication. However, challenges persist in defining lEV subtypes, achieving efficient purification and isolation, and accurately tracking their behavior in vivo. This review systematically summarizes recent advances in lEV research in tumor biology, highlights the distinctive functions of blebbisomes, and examines their translational potential in diagnostics and therapy. Key knowledge gaps are identified, including the need for single-vesicle multi-omics, advanced lipidomics, and engineered analytical platforms. We advocate for expanded investigation into lEVs as promising targets and tools in precision oncology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.